Relationship Between On-treatment Rescue Medication Use, Exacerbation Rates, and Health-related Quality of Life in Chronic Obstructive Pulmonary Disease: Post-hoc Analysis of the ETHOS Study (ID 369)
Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Hospitals Trust, Manchester, UK
Previously submitted to and presented at the American Thoracic Society 2022, 13–18 May.
Published abstract citation: Martinez FJ, Hurst JR, Darken P, Dorinsky P, Patel M. Relationship Between On-Treatment Rescue Medication Use, Exacerbation Rates, and Health-Related Quality of Life in Chronic Obstructive Pulmonary Disease: Post-Hoc Analysis of the ETHOS Study. American Thoracic Society - 118th International Conference. 2022;205:A1455. URL: https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts.A1455
Funding: This study was supported by AstraZeneca.
Conflicts of interest: Dave Singh reports personal fees from AstraZeneca during the conduct of the study; and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Genentech, GlaxoSmithKline, Glenmark, Gossamer Bio, Menarini, Mundipharma, Novartis, Peptinnovate, Pfizer, Pulmatrix, Theravance, and Verona, outside the submitted work.
Fernando J Martinez reports grants, personal fees, and non-financial support from AstraZeneca during the conduct of the study; grants, personal fees, and non-financial support from AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, Gala, GlaxoSmithKline, Metronic, Novartis, Polarean, Pulmatrix, Pulmonx, Sanofi/Regeneron, Sunovion, Tevan, Theravance/Viatris, and Verona; grants and personal fees from AstraZeneca, Chiesi, GlaxoSmithKline, and Sanofi/Regeneron.
John R Hurst reports consulting fees from AstraZeneca; speaker fees from AstraZeneca, Chiesi, Pfizer, and Takeda; and travel support from GlaxoSmithKline and AstraZeneca.
Patrick Darken and Mehul Patel are employees of AstraZeneca and hold stock and/or stock options in the company.
Paul Dorinsky is a former employee of AstraZeneca and previously held stock and/or stock options in the company.